[e-drug] Lessons from Malarone donation program

[Beverley Snell <bev@burnet.edu.au>]

E-drug: Lessons from Malarone donation program
---------------------------------------------

The following article in the Bulletin of the World Health 
Organisation is available in full at this URL
http://www.who.int/bulletin/pdf/2002/bul-10-E-2002/80(10)817-821.pdf
[URL needs repair]
The abstract appears below.  If you would like the full article but 
are unable to access it please contact me and I can attach a pdf 
version directly to you.  Beverley Snell - co-moderator 
<bev@burnet.edu.au>


A public-private partnership for malaria control: lessons from
the Malarone Donation Programme
A.B.O. Olukayode Oyediran,  Edward M. Ddumba, Samuel A. Ochola,
Adetokunbo O. Lucas, Kim Koporc, & Walter R. Dowdle
Bulletin of the World Health Organization 2002;80:817-821.

Abstract
In 1996, Glaxo Wellcome offered to donate up to a million treatment 
courses annually of Malarone, a new antimalarial, with a view to 
reducing the global burden of malaria. The Malarone Donation 
Programme (MDP) was established the following year. Eight pilot sites 
were selected in Kenya and Uganda to develop and evaluate an 
effective, locally sustainable donation strategy that ensured 
controlled and appropriate use of Malarone. The pilot programme 
targeted individuals who had acute uncomplicated Plasmodium 
falciparum malaria that had not responded to first-line treatments 
with chloroquine or sulfadoxine-pyrimethamine. Of the 161 079 
patients clinically diagnosed at the pilot sites as having malaria, 
1101 (0.68%) met all the conditions for participation and received 
directly observed treatment with Malarone. MDP had a positive effect 
at the pilot sites by improving the diagnosis and management of 
malaria. However, the provision of Malarone as a second-line drug at 
the district hospital level was not an efficient and effective use of 
resources. The number of deaths among children and adults ineligible 
for MDP at the pilot sites suggested that high priority should be 
given to meeting the challenges of malaria treatment at the community 
level.
Keywords Chloroguanide/supply and distribution/pharmacology; 
Naphthoquinones/supply and distribution/pharmacology; Anti-malarials/ 
supply and distribution; Malaria, Falciparum/drug therapy; Drug 
industry; Public sector; Private sector; Intersectoral cooperation; 
Pilot projects; Program evaluation; Kenya; Uganda.

-- 

Beverley Snell
Centre for International Health
Macfarlane Burnet Institute for Medical Research & Public Health
GPO Box 2284, Melbourne 3001 Australia

Telephone 613 9282 2115 / 9282 2275
Fax 61 3 9282 2144  or  9282 2100
Time zone: 11 hours ahead of GMT.
email <bev@burnet.edu.au>

Site: Alfred Medical Research & Education Precinct (AMREP),
corner Punt & Commercial Roads, Prahran 3181
__________________________________________
--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@usa.healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug